{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:15:57Z","timestamp":1790741757042,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ijcard.2024.131775","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T12:11:17Z","timestamp":1704802277000},"page":"131775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The impact of early in-hospital use of PCSK9 inhibitors on cardiovascular outcomes in acute coronary syndrome patients: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"399","author":[{"given":"Deng","family":"Yifan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Yubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao","family":"Jiapei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Shenghu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijcard.2024.131775_bb0005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5603\/KP.a2019.0017","article-title":"Landmark studies in coronary heart disease epidemiology. The Framingham heart study after 70 years and the seven countries study after 60 years[J]","volume":"77","author":"Cybulska","year":"2019","journal-title":"Kardiol. Pol."},{"issue":"3","key":"10.1016\/j.ijcard.2024.131775_bb0010","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.suc.2022.01.007","article-title":"Epidemiology of coronary artery disease[J]","volume":"102","author":"Duggan","year":"2022","journal-title":"Surg. Clin. North Am."},{"issue":"25","key":"10.1016\/j.ijcard.2024.131775_bb0015","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines[J]","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation."},{"issue":"1","key":"10.1016\/j.ijcard.2024.131775_bb0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [J]","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.ijcard.2024.131775_bb0025","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/clc.23725","article-title":"Lipid goal attainment in post-acute coronary syndrome patients in China: results from the 6-month real-world dyslipidemia international study II [J]","volume":"44","author":"Gong","year":"2021","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131775_bb0030","article-title":"PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations[J]","volume":"377","author":"Hao","year":"2022","journal-title":"BMJ."},{"issue":"3","key":"10.1016\/j.ijcard.2024.131775_bb0035","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/FJC.0000000000000706","article-title":"Alirocumab in acute myocardial infarction: results from the Virginia Commonwealth University Alirocumab response trial (VCU-AlirocRT) [J]","volume":"74","author":"Trankle","year":"2019","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"18","key":"10.1016\/j.ijcard.2024.131775_bb0040","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial[J]","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA."},{"issue":"6","key":"10.1016\/j.ijcard.2024.131775_bb0045","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.clinthera.2022.04.010","article-title":"Early initiation of evolocumab treatment in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention[J]","volume":"44","author":"Zhang","year":"2022","journal-title":"Clin. Ther."},{"issue":"4","key":"10.1016\/j.ijcard.2024.131775_bb0050","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2174\/1570161118666200616144141","article-title":"Efficacy and safety of evolocumab in reducing low-density lipoprotein cholesterol levels in Chinese patients with non-ST-segment elevation acute coronary syndrome","volume":"19","author":"Xu","year":"2021","journal-title":"Curr. Vasc. Pharmacol[J]."},{"issue":"20","key":"10.1016\/j.ijcard.2024.131775_bb0055","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)[J]","volume":"74","author":"Koskinas","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcard.2024.131775_bb0060","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1536\/ihj.22-052","article-title":"Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome[J]","volume":"63","author":"Hao","year":"2022","journal-title":"Int. Heart J."},{"issue":"11","key":"10.1016\/j.ijcard.2024.131775_bb0065","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.4244\/EIJ-D-22-00735","article-title":"Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial[J]","volume":"18","author":"Mehta","year":"2022","journal-title":"EuroIntervention."},{"issue":"1","key":"10.1016\/j.ijcard.2024.131775_bb0070","doi-asserted-by":"crossref","DOI":"10.15212\/CVIA.2022.0011","article-title":"Effects of loading-dose statins combined with PCSK9 inhibitor pre-treatment before primary percutaneous coronary intervention on the short-term prognosis in patients with ST-segment elevation myocardial infarction[J]","volume":"7","author":"Wang","year":"2022","journal-title":"CVIA."},{"key":"10.1016\/j.ijcard.2024.131775_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2022.01.058","article-title":"The trajectory of lipoprotein(a) during the peri- and early postinfarction period and the impact of proprotein convertase subtilisin\/kexin type 9 inhibition[J]","volume":"171","author":"Vavuranakis","year":"2022","journal-title":"Am. J. Cardiol."},{"issue":"7","key":"10.1016\/j.ijcard.2024.131775_bb0080","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1368-5031.2004.00188.x","article-title":"Improving lipid management--to titrate, combine or switch[J]","volume":"58","author":"Schuster","year":"2004","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ijcard.2024.131775_bb0085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2018.08.040","article-title":"Optimising treatment of hyperlipidaemia: quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk[J]","volume":"278","author":"Soran","year":"2018","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.ijcard.2024.131775_bb0090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2017.08.013","article-title":"Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the dyslipidemia international study II[J]","volume":"266","author":"Gitt","year":"2017","journal-title":"Atherosclerosis."},{"issue":"5","key":"10.1016\/j.ijcard.2024.131775_bb0095","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/14656566.2020.1714028","article-title":"An overview of rosuvastatin\/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia[J]","volume":"21","author":"Strilchuk","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.ijcard.2024.131775_bb0100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient[J]","volume":"16","author":"Cheeley","year":"2022","journal-title":"J. Clin. Lipidol."},{"issue":"6","key":"10.1016\/j.ijcard.2024.131775_bb0105","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/JCN.0b013e3181b4bab4","article-title":"Evidence-based guidelines for cardiovascular risk reduction: the safety and efficacy of high-dose statin therapy[J]","volume":"24","author":"Ashen","year":"2009","journal-title":"J. Cardiovasc. Nurs."},{"key":"10.1016\/j.ijcard.2024.131775_bb0110","article-title":"Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer\u2019s disease and Parkinson\u2019s disease: Mendelian randomisation study[J]","volume":"357","author":"Benn","year":"2017","journal-title":"BMJ."},{"issue":"2","key":"10.1016\/j.ijcard.2024.131775_bb0115","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J]","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"issue":"10106","key":"10.1016\/j.ijcard.2024.131775_bb0120","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial[J]","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ijcard.2024.131775_bb0125","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","article-title":"Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE[J]","volume":"147","author":"Gaba","year":"2023","journal-title":"Circulation"},{"issue":"S1","key":"10.1016\/j.ijcard.2024.131775_bb0130","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.3909\/ricm19S1S0002","article-title":"PCSK9 inhibitors: mechanism of action, efficacy, and safety[J]","volume":"19","author":"Roth","year":"2018","journal-title":"Rev. Cardiovasc. Med."},{"issue":"22","key":"10.1016\/j.ijcard.2024.131775_bb0135","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ijcard.2024.131775_bb0140","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.120.049447","article-title":"Clinical efficacy and safety of alirocumab after acute coronary syndrome according to achieved level of low-density lipoprotein cholesterol: a propensity score-matched analysis of the Odyssey outcomes trial[J]","volume":"143","author":"Schwartz","year":"2021","journal-title":"Circulation."},{"issue":"7","key":"10.1016\/j.ijcard.2024.131775_bb0145","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc. Imaging[J]"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324001050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324001050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:04:48Z","timestamp":1759093488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324001050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":29,"alternative-id":["S0167527324001050"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.131775","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of early in-hospital use of PCSK9 inhibitors on cardiovascular outcomes in acute coronary syndrome patients: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.131775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"131775"}}